Fig 1: TFEC regulates ILK transcription by binding to the ILK promoter. (A) CFs were transfected with a TFEC-OE plasmid for overexpression, and ILK mRNA levels were measured by qRT-PCR. (B) CFs were transfected with si-TFEC plasmid to silence TFEC, and ILK mRNA levels were assessed by qRT-PCR. (C–E) ILK protein expression was examined by western blotting and quantified. (F) ILK mRNA levels were measured by qRT-PCR. (G,H) Luciferase reporter assays in both 293T cells and CFs validated the transcriptional regulation of ILK by TFEC, which is mediated through direct binding to the ILK promoter. **p < 0.01 vs. OE-NC; ##p < 0.01 vs. si-NC; && p < 0.01 vs. indicated groups. (I) ChIP-qPCR analysis showing the enrichment of TFEC at the ILK promoter. Data are presented as fold enrichment relative to the IgG control (mean ± SD, n = 3 independent experiments). **p < 0.01 vs. IgG group. OE-NC: overexpression negative control (empty vector); si-NC: small interfering RNA negative control; si-TFEC: small interfering RNA against TFEC; TFEC-OE: TFEC-overexpressing vector; ChIP: Chromatin Immunoprecipitation.
Fig 2: Upregulation of TFEC and ILK in TGF-β1-induced cardiac fibroblasts (CFs). (A,B) An in vitro model of CFs was established using TGF-β1 induction. TFEC and ILK mRNA levels were assessed by qRT-PCR. (C) The representative western blotting results of TFEC and ILK protein. (D,E) The quantified protein expression levels of TFEC and ILK evaluated by western blotting. The mRNA and protein levels of TFEC and ILK were significantly elevated by TGF-β1. *p < 0.05 and **p < 0.01 compared with indicated group.
Fig 3: TFEC/ILK deficiency attenuates TGF-β1-induced fibrosis in cardiac fibroblasts (CFs). (A) CFs were transfected to create TFEC- or ILK-deficient cells, followed by TGF-β1 exposure. The mRNA levels of fibrosis markers (α-SMA, Collagen I, and Collagen III) were measured by qRT-PCR. (B,D) The representative western blotting results of α-SMA, Collagen I, and Collagen III and quantification results. (C,E) The representative western blotting results of Hippo signaling-related proteins (LATS1 and YAP) and quantification results. LATS1: large Tumor Suppressor Kinase 1; YAP: Yes-associated protein. Deficiency of TFEC/ILK inhibited TGF-β1-caused fibrosis and TGF-β1-activated Hippo signaling in CFs **p < 0.01 vs. Control; ##p < 0.01 vs. TGF-β1.
Fig 4: TFEC silencing reduced fibrosis in ISO-treated mice. (A,B) Immunohistochemical staining results to assess α-SMA and Collagen I expression in heart tissue from ISO-treated mice. (C) Sirius red staining results to visualize collagen fiber deposition in heart tissues of ISO-treated mice. TFEC silencing significantly reduced the expression of α-SMA and Collagen I and Sirius red staining in heart tissues from ISO-treated mice. (D) Representative images of immunohistochemical staining for Collagen I in mouse heart tissues from different groups. (E) Representative images of Sirius Red staining in mouse heart tissues from different groups. (F–K) The results of cardiac function (stroke volume, ejection fraction, and heart rate) in mice. ISO: isoproterenol; shNC: short hairpin RNA negative control; shTFEC: short hairpin RNA against TFEC. *: P < 0.05 between indicated groups.
Fig 5: The regulation of TFEC/ILK axis on the Akt/GSK3βsignaling pathway in cardiac fibroblasts and the regulation of miR-335-3p on myocardial fibrosis and TFEC. (A) CFs were transfected with TGF-β1, si-ILK, si- TFEC or si-NC and then stimulated with TGF-β1. Protein levels of p-Akt (Ser473), total Akt, p-GSK3β (Ser9), and total GSK3β were analyzed by Western blotting. (B) Multiple miRNAs, including miR-374-5p, miR-5096, miR-335-3p, miR-769-5p, miR-873-5p, and miR-506-5p, were predicted to have binding sites with the transcription factor TFEC. The expression levels of these miRNAs were examined. The level of miR-335-3p was significantly downregulated in the Myocardial Fibrosis tissue compared to Control. (C) CFs were transfected with a miR-335-3p inhibitor to reduce miR-335-3p levels, and protein expression of RUNX1 and TFEC was analyzed by western blotting. **p < 0.01 vs. indicated groups.
Supplier Page from Abcam for Anti-TFEC antibody